Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha variable 25 (TRAV25) is a segment of the alpha variable region of the T cell receptor (TCR) alpha chain. TCRs are heterodimeric membrane proteins found on T lymphocytes, crucial for antigen recognition as part of the adaptive immune response. The variable regions, including TRAV25, are generated by recombination of V (variable) and J (joining) gene segments during T cell development, allowing for the wide diversity of antigen recognition. The alpha-beta TCR recognizes peptide-MHC complexes displayed by antigen-presenting cells, initiating the signaling cascade required for T cell activation and immune defense. TRAV25 is not a full receptor on its own but rather one of many variable segments that, when combined in mature TCRs, provide the specificity needed for immune surveillance and response. In clinical research, engineering TCRs (using specific variable regions such as TRAV25) is explored for adoptive T cell transfer therapies in cancer and infectious disease contexts[1][3].
Targeting is generally through *adoptive T cell transfer* (engineered TCRs), where the mechanism involves antigen recognition presented on MHC complexes, leading to T cell activation and immune effector responses[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha variable 25 (TRAV25).